<iframe src="//www.googletagmanager.com/ns.html?id=GTM-MX3DVL" height="0" width="0" style="display:none;visibility:hidden"></iframe>Pestalozzi advised Johnson & Johnson's Swiss based Cilag International on its acquisition of Covagen AG | Pestalozzi Attorneys at Law

Pestalozzi advised Johnson & Johnson's Swiss based Cilag International on its acquisition of Covagen AG

08.2014

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAbtechnology platform. Covagen's lead product, COVA 322, a bispecific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb®, is in Phase 1b study for psoriasis and holds potential as a treatment for a broad range of inflammatory diseases including rheumatoid arthritis. Pestalozzi advised Cilag GmbH International on all Swiss legal and tax aspects of the acquisition.

To the top

Cookies

Okay
We use cookies in order to optimally design and continuously improve our website. By continuing to use the website you consent to the use of cookies. For further information about cookies please view our data protection statement.